Successful antiviral treatment of chronic hepatitis C in patients with rare comorbidities. Two case-reports
Journal Title: Annals of Hepatology - Year 2012, Vol 11, Issue 3
Abstract
Antiviral therapy in patients suffering from chronic hepatitis C virus (HCV) infection and rare comorbidities cannot be easily started, as it can reduce the likelihood of a good therapeutic response with an increased frequency of side effects. We report two patients presenting unusual comorbidities associated with chronic C hepatitis: one with the Ehlers-Danlos Syndrome (EDS), a rare genetic disease caused by a defect in collagen synthesis, the other one with the Charcot Marie Tooth (CMT) disease, an uncommon but severe form of demyelinating peripheral neuropathy. Both patients were successfully treated with pegylated Interferon (Peg-IFN) and ribavirin (RBV) combined therapy, with the achievement of a sustained viral response (SVR) and a low occurrence of adverse effects. Up to now there are no reports of patients suffering from chronic C hepatitis associated with these uncommon but severe comorbidities treated with antiviral therapy. In conclusion, in such clinical situations, anti-HCV therapy may be started and tailored, especially if the patient is highly motivated and if optimal predictors of response (i.e. young age, favourable genotype and low baseline viraemia) do exist.
Authors and Affiliations
Viola Guardigni, Gabriele Fabbri, Anastasio Grilli, Carlo Contini
Keywords
Related Articles
- EP ID EP78155
- DOI -
- Views 105
- Downloads 0
Dorsal root ganglionopathy in a hepatitis C patient: a case report
We report an unusual clinical presentation of dorsal root ganglionopathy in a hepatitis C patient with negative cryoglobulins characterized by both motor and sensory symptoms. This mixed clinical picture in a hepatitis C...
Platelet count/spleen diameter ratio as a predictor of esophageal varices in cirrhotic patients
Intestinal nuclear bile acid receptor FXR and cholestasis
Primary care practitioners survey of non-alcoholic fatty liver disease
Background. The rising incidence of non alcoholic fatty liver disease (NAFLD) mirrors the epidemics of obesity and metabolic syndrome. Primary care practitioners (PCPs) are central to management of patients with NAFLD, b...
The prevalence of nonalcoholic fatty liver disease in the Americas
Nonalcoholic fatty liver disease (NAFLD) is an alarming public health problem. The disease is one of the main causes of chronic liver disease worldwide and is directly linked to the increased prevalence of obesity and ty...